Agios Pharma Announces Topline Results From Phase 2 Trial Of Tebapivat, Oral Pyruvate Kinase Activator, In Patients Aged 16 Years Or Older With Sickle Cell Disease

뉴스 본문을 불러오고 있어요.

Agios Pharma Announces Topline Results From Phase 2 Trial Of Tebapivat, Oral Pyruvate Kinase Activator, In Patients Aged 16 Years Or Older With Sickle Cell Disease | 웨이프 WAPE

Agios Pharma Announces Topline Results From Phase 2 Trial Of Tebapivat, Oral Pyruvate Kinase Activator, In Patients Aged 16 Years Or Older With Sickle Cell Disease

기사 요약

관련 종목

댓글 —